Solid Biosciences Inc.
Solid Biosciences Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is Microdystrophin Gene Transfer Study in Adolescents and Children With DMD on October 15, 2026. There are 5 upcoming events on record.
Cash runway is approximately 24 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| October 15, 2026 | Microdystrophin Gene Transfer Study in Adolescents and Children With DMD | Trial Milestone | Phase 1/Phase 2 |
| May 6, 2027 | A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE) | Trial Milestone | Phase 1/Phase 2 |
| June 15, 2027 | A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) | Trial Milestone | Phase 1 |
| March 21, 2028 | A Study of SGT-212 Gene Therapy in Friedreich's Ataxia | Trial Milestone | Phase 1 |
| January 15, 2029 | A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE) | Trial Milestone | Phase 3 |
Track SLDB alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open SLDB in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| August 6, 2026 | 8-K filed: Other event | Filing | — |
| April 10, 2026 | 8-K filed: Leadership change | Corporate | — |
| March 12, 2026 | 8-K filed: Reg FD disclosure, Other event | Filing | — |
| March 6, 2026 | Quarterly results filed (8-K) | Earnings | — |
| November 3, 2025 | Quarterly results filed (8-K) | Earnings | — |
| June 13, 2025 | 8-K filed: Leadership change | Corporate | — |
| May 15, 2025 | 8-K filed: Other event | Filing | — |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.